PerkinElmer
check quantity

Yersinia enterocolitica - Xen25

Yersinia enterocolitica - Xen25 bioluminescent pathogenic bacteria for in vivo and in vitro drug discovery. This product was derived from the parental strain WS2589. Y. enterocolitica-Xen25 possesses a stable copy of the Photorhabdus luminescens lux operon on the bacterial chromosome.

Part Number 119233
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

For laboratory use only. This product is intended for animal research only and not for use in humans.

Overview

Infectious disease is a perennially important area for both life science research and drug discovery. Some of the first applications of IVIS® imaging technology were in tracking infections and monitoring host responses, and these applications are still at the forefront of research. PerkinElmer's bioluminescent infectious disease light-producing microorganisms have been developed to mimic both acute and chronic standard infection protocols presently used by researchers.

  • Engineered Bacterium: Yersinia enterocolitica - Xen25
  • Parental Strain: WS2589
  • In Vitro/Ex Vivo: Growth profiles
  • In Vivo: Not tested

Advantages of using bioluminescent light-producing microorganisms for drug discovery in vitro:

  • Rapid and readily amenable to high throughput screening, e.g., 96 or 384-well format
  • Sensitivity - subtle changes in cellular viability are rapidly detected
  • Inexpensive - no additional substrates needed for bacterial assays

Advantages of using bioluminescent light-producing microorganisms for drug discovery in vivo:

  • Rapid identification of lead drug candidates
  • Real-time efficacy data
  • May help to decrease drug failure by allowing disease relapse to be monitored in the same animal

Specifications

Gram Positive Gram Negative Gram negative
Luciferase Classification Bacterial luciferase
Optical Imaging Classification Bioluminescence Imaging
Product Brand Name XenoLight
Shipping Condition Ambient
Therapeutic Area Bacterial infection
Unit Size 1 agar plate
Resources, Events & More
  • All

Flyer

Technical Note

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB